AZ's Zavicefta Gains EU Positive Opinion For “Superbug” Infections
Executive Summary
The CHMP followed recent EMA guidance to take a flexible approach to drugs against multi-resistant pathogens when recommending approval for AstraZeneca’s latest antibacterial Zavicefta.
You may also be interested in...
AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D
AstraZeneca is selling its late-stage small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5bn, but the company – one of just a few big pharmas working in antibiotics R&D – says it will continue to study novel antibiotics via its MedImmune biologics division.
AstraZeneca, Allergan Sign Another Antibiotic Pact
Allergan Inc. and AstraZeneca plc will join forces to further develop and commercialize ATM-AVI, a fixed-dose antibiotic for the treatment of infections caused by metallo β-lactamase (MBL)-producing Gram-negative pathogens – bacteria for which there are few viable antibiotics.
Actavis antibiotic combo Avycaz OK'd for 2 infections
Actavis won the FDA's approval on 25 February to market Avycaz, an antibiotic combination containing ceftazidime and avibactam, to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).